# Financial Results for the Fiscal Year 2019, Ended December 31, 2019

Ι	Summary	Information	P.1
	1	Financial Results	P.1
	2	Financial Conditions	P.1
	3	Statement of Cash Flows	P.1
	4	Capital Expenditures	P.1
	5	Depreciation/Amortization	P.1
Π	Financial	Results for the FY2019	P.2
	1	Statement of Income	P.2
	2	Sales of Products	P.4
	3	Research and Development	P.5
	<b>F</b> '		D ¢
Ш	Financial	Forecasts for the FY2020	P.6
	1	Statement of Income	P.6
	2	Sales of Products	P.8

- X This material is prepared based on Japan GAAP.
- % Amounts are rounded down to the nearest million yen.
- The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein. Torii will not necessarily revise this material regardless of any new information, future events or

I orn will not necessarily revise this material regardless of any new information, future events or other results.

February 6, 2020



## I Summary Information

1	Financial	Results

(Millions of Yen)		FY2018	FY2019	Change	Change (%)	FY2020 forecast	Change	Change (%)
		А	В	B-A	(B-A)/A	С	С-В	(C-B)/B
Net sales		62,551	42,998	(19,553)	(31.3)	41,600	(1,398)	(3.3)
Operating income		4,951	1,430	(3,520)	(71.1)	3,000	1,569	109.7
Ordinary income		5,080	1,691	(3,388)	(66.7)	3,300	1,608	95.0
Net income		1,164	27,367	26,202	-	2,100	(25,267)	(92.3)
(Reference)								
R&D expenses		4,138	2,956	(1,181)	(28.5)	1,000	(1,956)	(66.2)
Earnings per share	(¥)	41.51	974.98	933.47		74.80	(900.18)	
(EPS)	(+)	41.51	574.50	555.47		71.00	(900.10)	
Return on equity (ROE)	(%)	1.3	27.3	26.0				
Ratio of ordinary income to total assets	(%)	4.9	1.4	(3.5)				
Ratio of operating income to net sales	(%)	7.9	3.3	(4.6)				
Return on assets (ROA)	(%)	1.1	22.5	21.4				

#### ② Financial Conditions

(Millions of Yen)		December 31, 2018	December 31, 2019	Change	Change (%)
		А	В	B-A	(B-A)/A
Total assets		103,253	139,943	36,690	35.5
Total equity		87,092	113,125	26,033	29.9
Equity ratio	(%)	84.3	80.8	(3.5)	
Book value per share (BPS)	(¥)	3,103.28	4,029.30	926.02	

#### ③ Statement of Cash Flows

(Millions of Yen)	FY2018	FY2019	Change
	А	В	B-A
Net cash provided by operating activities	8,259	42,499	34,239
Net cash provided by investing activities	(27,068)	2,099	29,168
Net cash used in financing activities	(1,432)	(1,433)	(1)
Cash and cash equivalents, end of period	15,654	58,819	43,165

#### Capital Expenditures

(Millions of Yen)	FY2018	FY2019	Change	Change (%)	FY2020 forecast	Change	Change (%)
	A	В	B-A	(B-A)/A	С	C-B	(C-B)/B
Capital expenditures	811	330	(480)	(59.3)	804	473	143.3
PP&E	660	203	(456)	(69.2)	541	337	165.4
Intangible assets	150	126	(24)	(15.9)	263	136	107.7

#### (5) Depreciation/Amortization

(Millions of Yen)	FY2018 <i>A</i>	FY2019 <i>B</i>	Change <i>B-A</i>	Change (%) (B-A)/A	FY2020 forecast c	Change <i>с-в</i>	Change (%) <i>(C-B)/B</i>
Depreciation and amortization of intangible assets	1,040	985	(54)	(5.2)	882	(103)	(10.5)
Amortization of long-term prepaid expenses	965	486	(479)	(49.7)	552	65	13.6

## II Financial Results for the FY2019


## ① Statement of Income

(Millions of Yen)	FY2018 <i>A</i>	FY2019 <i>B</i>	Change <i>B-A</i>	Change (%) <i>(B-A)/A</i>
Net sales	62,551	42,998	(19,553)	(31.3)
Sales of products	61,835	40,641	(21,193)	(34.3)
Sales of products				
(Except HIV infection)	40,386	40,641	255	0.6
Renal disease and hemodialysis	21,991	18,005	(3,986)	(18.1)
Skin disease	9,126	9,049	(77)	(0.8)
Allergens	3,803	7,627	3,824	100.6
Other	5,464	5,959	494	9.1
HIV infection	21,448	_	(21,448)	(100.0)
Other sales	716	2,356	1,640	229.0
Cost of sales	31,844	20,702	(11,141)	(35.0)
Cost of products sold	31,781	20,588	(11,193)	(35.2)
Other cost	63	114	51	81.5
Gross profit	30,707	22,295	(8,411)	(27.4)
Selling, general and administrative expenses	25,755	20,864	(4,890)	(19.0)
R&D expenses	4,138	2,956	(1,181)	(28.5)
Others	21,616	17,907	(3,709)	(17.2)
Operating income	4,951	1,430	(3,520)	(71.1)
Non-operating income and expenses	128	261	132	
Ordinary income	5,080	1,691	(3,388)	(66.7)
Extraordinary income and loss	(2,049)	36,008	38,058	
Income before income taxes	3,030	37,700	34,669	_
Income taxes	1,865	10,333	8,467	
Net income	1,164	27,367	26,202	_

## (Reference) Ratio to net sales

(%)	FY2018	FY2019	Change
	А	В	B-A
Cost of sales	50.9	48.1	(2.8)
SG&A	41.2	48.6	7.4
R&D expenses	6.6	6.9	0.3
Operating income	7.9	3.3	(4.6)
Ordinary income	8.1	3.9	(4.2)
Net income	1.9	63.6	61.7

[Factors in increase/decrease compared with the same term of the last fiscal year] Operating income (¥1,430 million : Decrease ¥3,520 million year-on-year)



Major factors in incre	lajor factors in increase/decrease				
Net sales	: Decrease with the termination of the exclusive rights to market the six anti-HIV drugs				
	in Japan and generic drugs(REMITCH)				
	Increase with the expansion of the products of Allergens and the six anti-HIV drugs				
	distribution fee income				
	※For sales of products, please refer to the next page				
Cost of sales	: Decrease in net sales				
R&D expenses	: Decrease in co-development expenses (JTS-661,JTE-052)				
Others	: Decrease with sales-linked expenses, personel expenses by buisiness struture reform				
	and cost reduction effect				

#### Ordinary income (¥1,691 million : Decrease ¥3,388 million year-on-year)

Special remarks: None

#### Net income (¥27,367 million : Increase ¥26,202 million year-on-year)

FY2019: Income from the termination of the exclusive rights to market the six anti-HIV drugs in Japan

	¥	40,614 million
Business structure reform expenses (Extra retirement allowance)	¥	4,504 million

### ② Sales of Products

(Millions of Yen)	FY2018	FY2019	Change	Change (%)
	A	В	B-A	(B-A)/A
Sales of Products	61,835	40,641	(21,193)	(34.3)
Sales of products(Except HIV infection)	40,386	40,641	255	0.6
[Renal disease and hemodialysis]				
REMITCH	11,598	8,693	(2,904)	(25.0
Oral anti-pruritus agent				
Riona	6,603	6,630	27	0.4
Agent for hyperphosphatemia				
KAYEXALATE 💥	1,963	1,907	(56)	(2.9
Agent for hyperkalemia				
Others	1,826	773	(1,052)	(57.6
Total	21,991	18,005	(3,986)	(18.1
[Skin disease]				
ANTEBATE 💥	5,536	5,439	(97)	(1.8
Topical corticosteroid				
LOCOID 💥	1,541	1,630	88	5.8
Topical corticosteroid				
ZEFNART	1,454	1,454	(0)	(0.0
Topical antifungal agent				
Others	593	524	(69)	(11.6
Total	9,126	9,049	(77)	(0.8
[Allergens]				
CEDARCURE X	405	3,654	3,249	801.8
Japanese cedar pollinosis (Allergen Immunotherapy)				
MITICURE 💥	1,247	2,749	1,502	120.4
House dust mite allergy (Allergen Immunotherapy)				
CEDARTOLEN 💥	1,859	924	(935)	(50.3
Japanese cedar pollinosis (Allergen Immunotherapy)				
Others	291	298	7	2.6
Total	3,803	7,627	3,824	100.6
[Other]				
BIO-THREE	2,682	2,843	161	6.0
Viable bacterial preparations				
Others	2,782	3,115	333	12.0
Total	5,464	5,959	494	9.1
HIV infection	21,448		(71 110)	(100.0
In-house products	21,440	—	(21,448)	(100.0

※ In-house products

## (References) Sales and ratio of in-house products

(Millions of Yen)		FY2018	FY2019	Change	Change (%)
		A	В	B-A	(B-A)/A
Sales of in-house products		15,855	19,068	3,212	20.3
Ratio of in-house	(%)	25.6	46.9	21.3	
product sales	(70)	25.0	-0.5	21.5	

#### ③ Research and Development

Development		Formulation/ Development stage (domestic)						
code	Indication	Route of administration	Phase I	Phase II	Phase III	Application	Approval	Remarks
Renal disease and	hemodialysis							
JTT-751 [Riona® Tablets]	Iron-deficiency anemia	Oral			Phase III			•Licensing agreement signed with Keryx for development and commercialization of hyperphosphatemia drug in Japan •Co-development with JT(Additional indication) •Riona filed by JT has been approved as a treatment of hyperphosphatemia in January 2014, and is being promoted and distributed by Torii.
JTZ-951	Anemia associated with chronic kidney disease	Oral				Application		•JT's original compound •Licensing agreement signed with JT for development and commercialization •NDA filing by JT in November, 2019
Skin disease								
JTE-052	Atopic dermatitis	Topical					Approval	•JT's original compound •Licensing agreement signed with JT for development and commercialization •NDA approval obtained by JT in January, 2020
FCORECTIM OintmentJ	Atopic dermatitis in children	Topical			Phase III			•JT's original compound •Licensing agreement signed with JT for development and commercialization
Allergens								
TO-203 「MITICURE® House Dust Mite Sublingual Tablets」	House dust mite induced allergic asthma (Allergen Immunotherapy)	Sublingual tablet		Phase (Study cor				Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house Examining the future development policy

Updates since the previous announcement on October 31, 2019 : •JTZ-951 NDA filing for the Treatment of Anemia Associated with CKD by JT on November 29, 2019.

Manufacturing and marketing approval of JTE-052(CORECTIM Ointment) for the indication of Atopic dermatitis by JT on January 23, 2020.

#### Additional Information

•In January 2020, Torii signed an exclusive license agreement with JT for co development and commercialization of tapinarof, a topical, therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in Japan. JT signed an exclusive license agreement on January 15, 2020, with Dermavant Sciences GmbH for the development and commercialization of tapinarof for dermatological diseases and conditions in Japan. (Torii and JT will jointly develop tapinarof.)

#### (Reference)

In October 2017, JT announced that the company signed an exclusive license agreement with EirGen Pharma Limited for the development and commercialization in Japan of calcifediol extended-release capsules (marketed by OPKO Health, Inc. in the U.S. under the brand name "RAYALDEE®") for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease, and Torii is expected to commercialize the product once it is approved.

Torii and its parent company, JT (specifically, the pharmaceutical division of the company) each leverage their own pharmaceutical product and service strengths. Torii is primarily responsible for manufacturing and marketing functions, while the parent company is responsible for research and development functions. For the clinical research and development of JT, please refer to the following posted on the company's website.

https://www.jt.com/investors/results/S information/pharmaceuticals/

## Ⅲ Financial Forecasts for the FY2020


## ① Statement of Income

(Millions of Yen)	FY2019	FY2020 forecast	Change	Change (%)
	А	В	B-A	(B-A)/A
Net sales	42,998	41,600	(1,398)	(3.3)
Sales of products	40,641	40,980	338	0.8
Renal disease and hemodialysis	18,005	14,870	(3,135)	(17.4)
Skin disease	9,049	9,290	240	2.7
Allergens	7,627	11,050	3,422	44.9
Other	5,959	5,770	(189)	(3.2)
Other sales	2,356	620	(1,736)	(73.7)
Cost of sales	20,702	20,000	(702)	(3.4)
Gross profit	22,295	21,600	(695)	(3.1)
SG&A	20,864	18,600	(2,264)	(10.9)
R&D expenses	2,956	1,000	(1,956)	(66.2)
Others	17,907	17,600	(307)	(1.7)
Operating income	1,430	3,000	1,569	109.7
Ordinary income	1,691	3,300	1,608	95.0
Net income	27,367	2,100	(25,267)	(92.3)

### (Reference) Ratio to net sales

(%)	FY2019	FY2020 forecast	Change
	A	В	B-A
Cost of sales	48.1	48.1	0.0
SG&A	48.6	44.7	(3.9)
R&D expenses	6.9	2.4	(4.5)
Operating income	3.3	7.2	3.9
Ordinary income	3.9	7.9	4.0
Net income	63.6	5.0	(58.6)

#### [Factors in increase/decrease compared with the FY2019]



#### Operating Income (¥3,000 million : Increase ¥1,569 million year-on-year)

Major factors in incre	ase/decrease
Net sales	: Decrease with the drug price revision implemented on October 1, 2019 and six anti-HIV drugs distribution fee income Increase with the expansion of the products of Allergens %For sales of products, please refer to the next page
Cost of sales	: Decrease with changes in sales mix among the products(increase in the in-house product ratio)
R&D expenses	: Decrease with business structure reform in last fiscal year(organizational reform) and co-development expenses(JTT-751)
Others	: Decrease with business structure reform in last fiscal year(personnel optimization, cost reductions, etc.)

#### Ordinary Income (¥3,300 million : increase ¥1,608 million year-on-year)

Special remarks: None

#### Net income (¥2,100 million : Decrease ¥25,267 million year-on-year)

FY2019 Income from the termination of the exclusive rights to market the six	anti-HI\	/ drugs in Japan
	¥	40,614 million
Business structure reform expenses (Extra retirement allowance)	¥	4,504 million

## ② Sales of Products

(Millions of Yen)	FY2019	FY2020 forecast	Change	Change (%)
	A	В	B-A	(B-A)/A
Sales of Products	40,641	40,980	338	0.8
[Renal disease and hemodialysis]				
Riona	6,630	6,620	(10)	(0.2)
Agent for hyperphosphatemia				
REMITCH	8,693	6,350	(2,343)	(27.0)
Oral anti-pruritus agent				
KAYEXALATE 💥	1,907	1,810	(97)	(5.1)
Agent for hyperkalemia				
Others	773	90	(683)	(88.4)
Total	18,005	14,870	(3,135)	(17.4)
[Skin disease]				
ANTEBATE X	5,439	4,920	(519)	(9.6)
Topical corticosteroid				
LOCOID 💥	1,630	1,490	(140)	(8.6)
Topical corticosteroid				
ZEFNART	1,454	1,360	(94)	(6.5)
Topical antifungal agent				
Others	524	1,520	995	189.6
Total	9,049	9,290	240	2.7
[Allergens]				
CEDARCURE X	3,654	6,340	2,685	73.5
Japanese cedar pollinosis (Allergen Immunotherapy)	-	,	·	
MITICURE X	2,749	4,150	1,400	50.9
House dust mite allergy (Allergen Immunotherapy)				
Others	1,223	560	(663)	(54.2)
Total	7,627	11,050	3,422	44.9
[Other]				
BIO-THREE	2,843	2,990	146	5.1
Viable bacterial preparations		,		
Others	3,115	2,780	(335)	(10.8)
Total	5,959	5,770	(189)	(3.2)

※ In-house products

## (References) Sales and ratio of in-house products

(Millions of Yen)	FY2019	FY2020 forecast	Change	Change (%)
	A	В	B-A	(B-A)/A
Sales of in-house products	19,068	21,600	2,531	13.3
Ratio of in-house (%) product sales	46.9	52.7	5.8	_